Increasing reports of COVID-19 symptom recurrence after treatment with the oral antiviral agent Paxlovid (nirmatrelvir/ritonavir) have been described the last few months. The Centers for Disease Control issued a health alert on May 24th, 2022 (https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf) about this issue, and this follow-up health alert addresses this phenomenon and describes what is known thus far, recommendations for quarantine and isolation from the California Department of Public Health (CDPH) and how to report symptom recurrence. The COVID-19 symptom recurrence reported thus far has been mild and does not indicate treatment failure. Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease. This information will be posted to the CDPH COVID-19 Therapeutics website shortly: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Treatments.aspx

Please click here for the full language of the Health Update.

Free viewers are required for some of the attached documents.
They can be downloaded by clicking on the icons below.

Acrobat Reader Windows Media Player Word Viewer Excel Viewer PowerPoint Viewer